Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Roxadustat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,694Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roxadustat Gains FDA Orphan Status for Myelodysplastic Syndromes
    Roxadustat Gains FDA Orphan Status for Myelodysplastic Syndromes

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205285/33525/en/Roxadustat-Granted-Orphan-Drug-Designation-for-the-Treatment-of-Myelodysplastic-Syndromes-by-the-U-S-Food-and-Drug-Administration.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    FibroGen publishes Ph 1 study results of FG-3246 in Prostate Cancer
    FibroGen publishes Ph 1 study results of FG-3246 in Prostate Cancer

    28 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/28/3051262/33525/en/FibroGen-Announces-Publication-of-Results-from-Phase-1-Monotherapy-Study-of-FG-3246-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer-in-the-Journal-of-Clinical-Onco.html

    GLOBENEWSWIRE
    28 Mar 2025
    Share Share
    FibroGen to Present at H.C. Wainwright 26th Annual Global Conference
    FibroGen to Present at H.C. Wainwright 26th Annual Global Conference

    03 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/03/2940091/33525/en/FibroGen-to-Present-at-the-H-C-Wainwright-26th-Annual-Global-Investment-Conference.html

    GLOBENEWSWIRE
    03 Sep 2024
    Share Share
    AstraZeneca finally drops roxadustat US rights
    AstraZeneca finally drops roxadustat US rights

    28 Feb 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/astrazeneca-finally-drops-roxadustat-us-rights-after-fda-rejection-trial-failure

    FIERCE PHARMA
    28 Feb 2024
    Share Share
    FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States
    FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States

    26 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/26/2835490/33525/en/FibroGen-Regains-All-Rights-to-Roxadustat-from-AstraZeneca-in-the-United-States-and-Other-AstraZeneca-Territories-Except-China-and-South-Korea.html

    GLOBENEWSWIRE
    26 Feb 2024
    Share Share
    FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat
    FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat

    09 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/09/2793446/33525/en/FibroGen-Presents-Data-from-Phase-3-MATTERHORN-Trial-of-Roxadustat-in-Patients-with-Anemia-of-Lower-Risk-Transfusion-Dependent-Myelodysplastic-Syndromes-at-American-Society-of-Hema.html

    GLOBENEWSWIRE
    09 Dec 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.